The findings may help explain why women with bladder cancer are often diagnosed at a later stage in the disease and have worse mortality than men.
The study, presented by Jeffrey Bassett, M.D., MPH, fellow in Urologic Oncology, and Principal Investigator Daniel Barocas, M.D., MPH, assistant professor of Urologic Surgery, was shared during the American Urological Association (AUA) annual conference held May 16 - 21 in Orlando, Florida, and was highlighted during the AUA press program.
Blood in the urine is often the first sign of bladder cancer. The AUA recommends that everyone over 35 with hematuria not due to a benign cause receive an evaluation that includes looking inside the bladder (cystoscopy) as well as imaging of the urinary tract, usually with a CT scan.
For this study, investigators reviewed the medical records of a random sample of 9,211 Medicare beneficiaries diagnosed with hematuria between January 2009 and June 2010. Only 17 percent of females with a diagnosis of hematuria from their primary care provider were referred to a urologist for a diagnostic workup within 180 days, compared to 39 percent of men. Receipt of a complete evaluation did not differ by race.
"The data in the literature suggest that the misdiagnosis and treatment of hematuria in women as urinary tract infection is one of the main reasons they present with more advanced stage bladder cancer at diagnosis," said Bassett.
Some of the difference may be clinical decision-making by physicians who know that women are less likely to have bladder cancer than men. But Barocas said the disparities suggest primary care physicians may need to be more vigilant.
"We are missing opportunities to diagnose these cancers early enough and it's increasing the treatment burden and mortality for women. Because we see such advanced disease in women and they are worked up for hematuria so much less frequently, there may be a need to figure out how to risk-stratify women to know whether or not they need a workup," said Barocas.